Loading
A phase 2/3 trial of tirapazamine in hepatocellular carcinoma, run by Zhejiang Raygene Pharmaceuticals Co., Ltd, now recruiting.
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. is a phase 2/3 interventional study registered as NCT06844357 by Zhejiang Raygene Pharmaceuticals Co., Ltd, with 300 participants planned, started 2025-03-27 and due to reach its primary completion in 2029-04-01. Interventions recorded: tirapazamine, Transarterial Embolization (TAE) and TACE.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/